Schreiber S, Peyrin-Biroulet L, Loftus Jr .，等(2019)Vedolizumab与Adalimumab在活动性溃疡性结肠炎患者中的双盲、双假、随机对照试验

{"title":"Schreiber S, Peyrin-Biroulet L, Loftus Jr .，等(2019)Vedolizumab与Adalimumab在活动性溃疡性结肠炎患者中的双盲、双假、随机对照试验","authors":"X. Tréton","doi":"10.3166/cer-2019-0098","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":56167,"journal":{"name":"Colon and Rectum","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"6","resultStr":"{\"title\":\"VARSITY: a Double-Blind, Double-Dummy, Randomised, Controlled Trial of Vedolizumab Versus Adalimumab in Patients with Active Ulcerative Colitis Schreiber S, Peyrin-Biroulet L, Loftus Jr EV, et al (2019) ECCO, OP 34\",\"authors\":\"X. Tréton\",\"doi\":\"10.3166/cer-2019-0098\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":56167,\"journal\":{\"name\":\"Colon and Rectum\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Colon and Rectum\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3166/cer-2019-0098\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Colon and Rectum","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3166/cer-2019-0098","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}